Table 7 The association of antihypertensive drugs with VAF
From: Pharmaceutical prevention strategy for arteriovenous fistula and arteriovenous graft failure
Author | Design | N (Control) | Exposure Timing | Outcome (duration) | VAF development |
|---|---|---|---|---|---|
Gradzki et al [84] | Retrospective | 121 (96) | ACE-I Various | Primary AVG failure (1 month to 5 years) | Lower risk (HR 0.47, 95% CI 0.23–0.93, P < 0.03) |
Sajgure et al [83] | Retrospective | 266 (142) | ACE-I Various | Time to AVG failure | Lower risk (671 vs. 459 days, P = 0.012) |
Jackson et al [85] | Retrospective | 332 (263) | ARB Various | Primary patency rates of VA (2 years) | Lower risk (AVF: HR 0.35, 95% CI 0.16–0.76, P = 0.08) (AVG: HR 0.41, 95% CI 0.18–0.95, P = 0.039) |
Chen et al [82] | Retrospective | 42244 (18480) | ACE-I ARB CCB Various | Primary patency rates of VA | Lower risk (AVF: HR 0.586 for ACE-I, 0.532 for ARB, 0.485 for CCB) (AVG: HR 0.557 for ACE-I, 0.536 for ARB, 0.482 for CCB) |